Physician profile
Michael Lauer
NPI 1407890536
$2,329.31
in general payments reported to CMS, 2019-2025
11 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,245 · 2020: $114 · 2021: $170 · 2022: $507 · 2024: $181 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $293.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,582.51 | 2019-2025 | |
| Boston Scientific Corporation | $322.05 | 2022-2025 | General - Structural Heart, Avvigo Guidance System, Opticross |
| Abbott Laboratories | $227.30 | 2020-2022 | |
| Shockwave Medical, INC | $84.32 | 2022 | |
| Bracco Diagnostics INC. | $35.97 | 2024 | |
| Livanova USA, INC. | $24.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.78 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.55 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.88 | 2024 | Lifevest |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.